Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    David Z D'Argenio, PhD

    TitleProfessor
    SchoolViterbi School of Engineering, BME
    DepartmentBiomedical Simulations Resource
    AddressDRB 154
    University Park Campus
    Los Angeles California 90089-1111
    Phone+1 213 740 0341
    Emaildargenio@usc.edu
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      David Z. D'Argenio received his Bachelors degree in Electrical Engineering from the University of Dayton in 1972, M.S. in Electrical Engineering from the Pennsylvania State University in 1974, and Ph.D. in Biomedical Engineering from USC in 1979. From 1993 to 1995 he served as Associate Dean for Academic Affairs in the School of Engineering and from 1996 to 2003 as Chairman of the Department of Biomedical Engineering. He also served as Interim Director of the Alfred E. Mann Institute for Biomedical Engineering from 1998-1999. Professor D'Argenio also serves on the Board of Trustees of the House Ear Institute and currently serves as the Chair of the Board.


      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Bensman TJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio D, Beringer PM. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis. Antimicrob Agents Chemother. 2017 Oct; 61(10). PMID: 28784670.
        View in: PubMed
      2. Dolton MJ, D'Argenio D. Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding. J Antimicrob Chemother. 2017 Apr 01; 72(4):1129-1136. PMID: 28039274.
        View in: PubMed
      3. Brown AN, Gallegos KM, D'Argenio D, Drusano GL. Reply to Scagnolari et al. J Infect Dis. 2017 Feb 01; 215(3):493-494. PMID: 28003357.
        View in: PubMed
      4. Song G, Pacini G, Ahrén B, D'Argenio D. Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice. Peptides. 2017 Feb; 88:74-79. PMID: 28012858.
        View in: PubMed
      5. Zhang Y, D'Argenio D. Feedback control indirect response models. J Pharmacokinet Pharmacodyn. 2016 Aug; 43(4):343-58. PMID: 27394724.
        View in: PubMed
      6. Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio D. Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT Pharmacometrics Syst Pharmacol. 2016 Feb; 5(2):65-73. PMID: 26933517; PMCID: PMC4761234.
      7. Weiss M, Tura A, Kautzky-Willer A, Pacini G, D'Argenio D. Human insulin dynamics in women: a physiologically based model. Am J Physiol Regul Integr Comp Physiol. 2016 Feb 01; 310(3):R268-74. PMID: 26608654; PMCID: PMC4796751 [Available on 02/01/17].
      8. Wu LS, Rower JE, Burton JR, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio D, Kiser JJ. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2015 Apr; 59(4):2179-88. PMID: 25645847; PMCID: PMC4356818.
      9. Zhang Y, Hsu CP, Lu JF, Kuchimanchi M, Sun YN, Ma J, Xu G, Zhang Y, Xu Y, Weidner M, Huard J, D'Argenio D. FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. J Pharmacokinet Pharmacodyn. 2014 Dec; 41(6):675-91. PMID: 25326874; PMCID: PMC4226810.
      10. Wang K, D'Argenio D, Acosta EP, Sheth AN, Delille C, Lennox JL, Kerstner-Wood C, Ofotokun I. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients. Clin Pharmacokinet. 2014 Apr; 53(4):361-71. PMID: 24311282; PMCID: PMC3962720.
      11. Zhou A, Pacini G, Ahrén B, D'Argenio D. Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice. Diabetologia. 2014 Apr; 57(4):801-8. PMID: 24370975; PMCID: PMC3947415.
      12. Marmarelis VZ, Shin DC, Zhang Y, Kautzky-Willer A, Pacini G, D'Argenio D. Analysis of intravenous glucose tolerance test data using parametric and nonparametric modeling: application to a population at risk for diabetes. J Diabetes Sci Technol. 2013 Jul 01; 7(4):952-62. PMID: 23911176; PMCID: PMC3879759.
      13. Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, Rosen KE, D'Argenio D. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy. AAPS J. 2013 Apr; 15(2):559-70. PMID: 23413101; PMCID: PMC3675747.
      14. Wu CC, D'Argenio D, Asgharzadeh S, Triche T. TARGETgene: a tool for identification of potential therapeutic targets in cancer. PLoS One. 2012; 7(8):e43305. PMID: 22952662; PMCID: PMC3432038.
      15. Kay BP, Hsu CP, Lu JF, Sun YN, Bai S, Xin Y, D'Argenio D. Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab. J Pharmacokinet Pharmacodyn. 2012 Oct; 39(5):577-90. PMID: 22932917; PMCID: PMC3487388.
      16. Kiser JJ, Zhu R, D'Argenio D, Cotton MF, Bobat R, McSherry GD, Madhi SA, Carey VJ, Seifart HI, Werely CJ, Fletcher CV. Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. Ther Drug Monit. 2012 Aug; 34(4):446-51. PMID: 22695364; PMCID: PMC3397663.
      17. D'Argenio D, Gastonguay MR, Brundage RC, Miller R, Tannenbaum SJ, Pfister M. Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics. J Pharmacokinet Pharmacodyn. 2012 Feb; 39(1):3. PMID: 22219000.
        View in: PubMed
      18. Beumer JH, Parise RA, Kanterewicz B, Petkovich M, D'Argenio D, Hershberger PA. A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay. Steroids. 2012 Apr; 77(5):477-83. PMID: 22285938; PMCID: PMC3303948.
      19. Coatrieux JL, Frangi AF, Peng GC, D'Argenio D, Marmarelis VZ, Michailova A. Editorial: TBME Letters special issue on multiscale modeling and analysis in computational biology and medicine--part-2. IEEE Trans Biomed Eng. 2011 Dec; 58(12):3434-9. PMID: 22105190; PMCID: PMC3958427.
      20. Beringer PM, Owens H, Nguyen A, Benitez D, Rao A, D'Argenio D. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012 Jan; 56(1):70-4. PMID: 22024822; PMCID: PMC3256044.
      21. Frangi AF, Coatrieux JL, Peng GC, D'Argenio D, Marmarelis VZ, Michailova A. Editorial: Special issue on multiscale modeling and analysis in computational biology and medicine--part-1. IEEE Trans Biomed Eng. 2011 Oct; 58(10):2936-42. PMID: 21937299.
        View in: PubMed
      22. Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D'Argenio D, Fletcher CV. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol. 2012 Apr; 52(4):511-9. PMID: 21558457; PMCID: PMC3182303.
      23. Chan HM, Jain R, Ahrén B, Pacini G, D'Argenio D. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. Am J Physiol Regul Integr Comp Physiol. 2011 May; 300(5):R1126-33. PMID: 21307364; PMCID: PMC3293513.
      24. D'Argenio D, Mager DE. Bridging pharmacology and pathophysiology via systems modeling. J Clin Pharmacol. 2010 Sep; 50(9 Suppl):56S-57S. PMID: 20881218; PMCID: PMC3125016.
      25. Brundage RC, Pfister M, D'Argenio D, Gastonguay MR, Miller R, Tannenbaum SJ. ACoP: the tools, carpenters, and architects building the discipline of pharmacometrics. J Clin Pharmacol. 2010 Sep; 50(9 Suppl):7S-8S. PMID: 20881212.
        View in: PubMed
      26. Pfister M, Brundage RC, Gastonguay MR, Miller R, Tannenbaum SJ, D'Argenio D. Defining the future of pharmacometrics: the American Society of Pharmacometrics. J Clin Pharmacol. 2010 Sep; 50(9 Suppl):158S. PMID: 20881230.
        View in: PubMed
      27. Pfister M, D'Argenio D. The emerging scientific discipline of pharmacometrics. J Clin Pharmacol. 2010 Sep; 50(9 Suppl):6S. PMID: 20881211.
        View in: PubMed
      28. Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, Clausen DM, D'Argenio D, Ames MM, Hershberger PA, Parise RA, Bai L, Covey JM, Egorin MJ. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemother Pharmacol. 2011 Feb; 67(2):421-30. PMID: 20443002; PMCID: PMC2954253.
      29. Wu CC, Asgharzadeh S, Triche TJ, D'Argenio D. Prediction of human functional genetic networks from heterogeneous data using RVM-based ensemble learning. Bioinformatics. 2010 Mar 15; 26(6):807-13. PMID: 20134029; PMCID: PMC2832827.
      30. Lee SS, Ghosn C, Yu Z, Zacharias LC, Kao H, Lanni C, Abdelfattah N, Kuppermann B, Csaky KG, D'Argenio D, Burke JA, Hughes PM, Robinson MR. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010 Apr; 51(4):2135-8. PMID: 20019364.
        View in: PubMed
      31. Wang X, Schumitzky A, D'Argenio D. Population Pharmacokinetic/Pharmacodyanamic Mixture Models via Maximum a Posteriori Estimation. Comput Stat Data Anal. 2009 Oct 01; 53(12):3907-3915. PMID: 20161085.
        View in: PubMed
      32. Jacob E, Scorsone K, Blaney SM, D'Argenio D, Berg SL. Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatr Blood Cancer. 2008 Apr; 50(4):757-60. PMID: 17849472; PMCID: PMC2975705.
      33. Wang J, Weiss M, D'Argenio D. A note on population analysis of dissolution-absorption models using the inverse Gaussian function. J Clin Pharmacol. 2008 Jun; 48(6):719-25. PMID: 18359921; PMCID: PMC2648518.
      34. Beumer JH, Eiseman JL, Parise RA, Florian JA, Joseph E, D'Argenio D, Parker RS, Kay B, Covey JM, Egorin MJ. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemother Pharmacol. 2008 Aug; 62(3):457-64. PMID: 18008070; PMCID: PMC2677692.
      35. Wang X, Schumitzky A, D'Argenio D. Nonlinear Random Effects Mixture Models: Maximum Likelihood Estimation via the EM Algorithm. Comput Stat Data Anal. 2007 Aug 15; 51(12):6614-6623. PMID: 19756256.
        View in: PubMed
      36. Beumer JH, Joseph E, Egorin MJ, Parker RS, D'argenio DZ, Covey JM, Eiseman JL. A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice. Clin Cancer Res. 2006 Oct 01; 12(19):5826-33. PMID: 17020990.
        View in: PubMed
      37. Zhou Z, Rodman JH, Flynn PM, Robbins BL, Wilcox CK, D'Argenio D. Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother. 2006 Aug; 50(8):2686-94. PMID: 16870759; PMCID: PMC1538647.
      38. Horton TM, Gannavarapu A, Blaney SM, D'Argenio D, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23. PMID: 16292537.
        View in: PubMed
      39. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, Lyubimov AV, Chen YF, D'Argenio D, Egorin MJ. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res. 2005 May 15; 11(10):3862-8. PMID: 15897587.
        View in: PubMed
      40. Bading JR, Yoo PB, Fissekis JD, Alauddin MM, D'Argenio D, Conti PS. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. Cancer Res. 2003 Jul 01; 63(13):3667-74. PMID: 12839957.
        View in: PubMed
      41. Xu L, Eiseman JL, Egorin MJ, D'Argenio D. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn. 2003 Jun; 30(3):185-219. PMID: 14571691.
        View in: PubMed
      42. Zamboni WC, D'Argenio D, Stewart CF, MacVittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, Egorin MJ. Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res. 2001 Aug; 7(8):2301-8. PMID: 11489805.
        View in: PubMed
      43. Drusano GL, D'Argenio D, Preston SL, Barone C, Symonds W, LaFon S, Rogers M, Prince W, Bye A, Bilello JA. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother. 2000 Jun; 44(6):1655-9. PMID: 10817724; PMCID: PMC89928.
      44. Snyder S, D'Argenio D, Weislow O, Bilello JA, Drusano GL. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother. 2000 Apr; 44(4):1051-8. PMID: 10722511; PMCID: PMC89812.
      45. Drusano GL, D'Argenio D, Symonds W, Bilello PA, McDowell J, Sadler B, Bye A, Bilello JA. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother. 1998 Sep; 42(9):2153-9. PMID: 9736527; PMCID: PMC105760.
      46. D'Argenio D, Rodman JH. Targeting the systemic exposure of teniposide in the population and the individual using a stochastic therapeutic objective. J Pharmacokinet Biopharm. 1993 Apr; 21(2):223-51. PMID: 8229682.
        View in: PubMed
      47. D'Argenio D. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math Biosci. 1990 Apr; 99(1):105-18. PMID: 2134510.
        View in: PubMed
      48. Maneval DC, D'Argenio D, Wolf W. A kinetic model for 99mTc-DMSA in the rat. Eur J Nucl Med. 1990; 16(1):29-34. PMID: 2155115.
        View in: PubMed
      49. D'Argenio D, Schumitzky A, Wolf W. Simulation of linear compartment models with application to nuclear medicine kinetic modeling. Comput Methods Programs Biomed. 1988 Jul-Aug; 27(1):47-54. PMID: 3409681.
        View in: PubMed
      50. Katz D, D'Argenio D. Implementation and evaluation of control strategies for individualizing dosage regimens, with application to the aminoglycoside antibiotics. J Pharmacokinet Biopharm. 1986 Oct; 14(5):523-37. PMID: 3806374.
        View in: PubMed
      51. D'Argenio D, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979 Mar; 9(2):115-34. PMID: 761456.
        View in: PubMed
      David's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department